133 related articles for article (PubMed ID: 29415745)
1. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A; Sarin KY; Petersen AK; Pichard DC; Wolters PL; Erickson G; Lessing AJ; Li P; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR
Clin Trials; 2024 Feb; 21(1):67-72. PubMed ID: 37269078
[TBL] [Abstract][Full Text] [Related]
3. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report.
Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T
J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958
[TBL] [Abstract][Full Text] [Related]
4. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
5. [Neurofibromas in Type I Neurofibromatosis. Description of a clinical case and literature review].
Del Puerto C; Aspee M; Downey C
Andes Pediatr; 2022 Oct; 93(5):741-748. PubMed ID: 37906895
[TBL] [Abstract][Full Text] [Related]
6. Receptor of ghrelin is expressed in cutaneous neurofibromas of individuals with neurofibromatosis 1.
Rozza-de-Menezes RE; Gaglionone NC; Andrade-Losso RM; Siqueira OHK; Almeida LM; Peruzini KDS; Guimarães-Filho MAC; Brum CI; Geller M; Cunha KS
Orphanet J Rare Dis; 2017 Dec; 12(1):186. PubMed ID: 29262839
[TBL] [Abstract][Full Text] [Related]
7. The development of cutaneous neurofibromas.
Jouhilahti EM; Peltonen S; Callens T; Jokinen E; Heape AM; Messiaen L; Peltonen J
Am J Pathol; 2011 Feb; 178(2):500-5. PubMed ID: 21281783
[TBL] [Abstract][Full Text] [Related]
8. Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1.
Tucker T; Riccardi VM; Sutcliffe M; Vielkind J; Wechsler J; Wolkenstein P; Friedman JM
J Histochem Cytochem; 2011 Jun; 59(6):584-90. PubMed ID: 21525187
[TBL] [Abstract][Full Text] [Related]
9. [Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1 : Operation of neurofibroma improves quality of life while having moderate complications].
Walz B; Pfefferle V; Häfner HM; Kofler L
Dermatologie (Heidelb); 2022 Dec; 74(12):961-968. PubMed ID: 37728798
[TBL] [Abstract][Full Text] [Related]
10. Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.
Cunha KS; Rozza-de-Menezes RE; Andrade RM; Theos A; Luiz RR; Korf B; Geller M
Orphanet J Rare Dis; 2014 Dec; 9():202. PubMed ID: 25475340
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
[TBL] [Abstract][Full Text] [Related]
12. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
13. Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.
Matthies L; Amir-Kabirian H; Gebrekidan MT; Braeuer AS; Speth US; Smeets R; Hagel C; Gosau M; Knipfer C; Friedrich RE
PLoS One; 2024; 19(4):e0302017. PubMed ID: 38603731
[TBL] [Abstract][Full Text] [Related]
14. A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L; Bergqvist C; Sarin KY; Plotkin SR; Moertel C; Petersen AK; Cannon A; Berman Y; Pichard DC; Röhl C; Lessing A; Brizion B; Peiffer B; Ravaud P; Tran VT; Armand ML; Moryousef S; Ferkal S; Jannic A; Ezzedine K; Wolkenstein P;
Br J Dermatol; 2024 Jan; 190(2):216-225. PubMed ID: 37877514
[TBL] [Abstract][Full Text] [Related]
15. Clinical picture and treatment of cutaneous lesions in patients with neurofibromatosis type 1.
Fijałkowska M; Antoszewski B
Postepy Dermatol Alergol; 2020 Oct; 37(5):781-784. PubMed ID: 33240020
[TBL] [Abstract][Full Text] [Related]
16. Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
Br J Dermatol; 2024 Jan; 190(2):e20. PubMed ID: 38262593
[No Abstract] [Full Text] [Related]
17. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
18. Real-world Settings for the Surgical Treatment of Neurofibroma in Patients with Neurofibromatosis Type 1.
Ota M; Nobeyama Y; Asahina A
JMA J; 2024 Apr; 7(2):205-212. PubMed ID: 38721077
[TBL] [Abstract][Full Text] [Related]
19. How to score the impact of treatment on cutaneous neurofibromas in clinical trials.
Ortonne N
Br J Dermatol; 2024 Jan; 190(2):147-148. PubMed ID: 38084905
[No Abstract] [Full Text] [Related]
20. Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.
Mazuelas H; Magallón-Lorenz M; Uriarte-Arrazola I; Negro A; Rosas I; Blanco I; Castellanos E; Lázaro C; Gel B; Carrió M; Serra E
JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
